Table 1.

Clinicopathological characteristics of the studied population (n = 290).

Patient Features		Number of Patients(n = 290)	%
Age (years), median (min to max)		57.72	[28.54–89.10]
	<55	129	44.5
	≥55	161	55.5
Tumor size
	T1	134	46.2
	T2	138	47.6
	T3/T4	18	6.2
Nodal status
	N−	189	65.2
	N+	101	34.8
Histological grade (4 missing values)
	1–2	66	23.1
	3	220	76.9
Histology (3 missing values)
	Ductal	238	82.9
	Lobular	15	5.2
	Other (1)	34	11.9
Adjuvant chemotherapy (1 missing value)
	No	71	24.6
	Yes	218	75.4
Basal-like phenotype (2 missing value)
	No	101	35.1
	Yes (basal)	187	64.9
Molecular apocrine phenotype (17 missing values)
	No	159	58.2
	Yes (molecular apocrine)	114	41.8
TIL %, median (6 missing values)
	<5%	134	47.2
	≥5%	150	52.8
CD3+ cell density (2 missing values)
	Low	144	50.0
	High	144	50.0
CD8+ cell density (6 missing values)
	Low	142	50.0
	High	142	50.0
PD-L1TC (24 missing values)
	<1%	119	44.7
	≥1%	147	55.3
PD-L1SC (27 missing values)
	0	48	18.3
	[0–10]	85	32.3
	[10–50]	72	27.4
	≥50	58	22.1
PD-1SC (21 missing values)
	0	69	25.7
	[0–10]	72	26.8
	[10–50]	106	39.4
	≥50	22	8.2
CD11b+ cell density (15 missing values)
	Low	137	49.8
	High	138	50.2
CD66b+ cell density (14 missing values)
	Low	138	50.0
	High	138	50.0
CXCR2+ cell density (3 missing values)
	Low	144	50.2
	High	143	49.8

Footnote: Basal-like phenotype was considered in the case of positive staining for cytokeratin 5/6 and/or EGFR (>10% of tumor cells stained in IHC); Molecular apocrine phenotype was defined in TNBC tumors that express both androgen receptor (AR) and Forkhead box protein A1 (FOXA1) biomarkers; TILs: tumor-infiltrating lymphocytes according to Salgado guidelines [40]; PD-L1: programmed cell death ligand 1; PD-1: programmed cell death 1; TC: tumor cells; SC: stromal cells. ⁽¹⁾ Seven metaplastic, seven invasive papillary, seven medullary, six mixed invasive, two apocrine, one adenoid cystic, one neuroendocrine, one mucinous, one polymorphous carcinoma and one malignant myoepithelioma.